Article
Clinical Performance of the BD Onclarity Extended Genotyping Assay for the Management of Women Positive for Human Papillomavirus in Cervical Cancer Screening.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology - 1 Apr 2022
Volesky Karena D, Magnan Sindy, Mayrand Marie-Hélène, Isidean Sandra D, El-Zein Mariam, Comète Emilie, Franco Eduardo L, Coutlée François
Abstract excerpt
BACKGROUND: Among women whose cervical specimens tested positive for high-risk human papillomaviruses (hrHPV) via the Hybrid Capture 2 assay in the Canadian Cervical Cancer Screening Trial (CCCaST), we assessed hrHPV genotype concordance between BD Onclarity HPV Assay and Roche's Linear Array, overall and stratified by hrHPV viral load. We also evaluated the performance of cytology, cytology combined with hrHPV...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.